Teppei Sakoda

Disease-related baseline cerebrospinal fluid proteomic variation refines biomarker interpretation before CAR-T therapy

Tomoko Nomiyama, Daiki Setoyama, Ikumi Yamanaka, Masatoshi Shimo et autres

Abstract Pre-infusion cerebrospinal fluid (CSF) proteomics may enable risk stratification for immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric antigen receptor T-cell therapy, but disease-specific baseline variation may influence biomarker interpretation. We compared pre-infusion CSF proteomic profiles from 28 patients with diffuse …

jp (code pays fourni par la source)

Early prediction of ICANS using CRS characteristics in B-cell lymphoma patients receiving CAR-T therapy

H. Nishihara, Fumiaki Jinnouchi, Daisuke Ishihara, Hiroshi Imanaga et autres

jp (code pays fourni par la source)

Fulminant drug-induced immune thrombocytopenia in polycystic kidney disease with cyst infection

Narumichi Iwamura, Yuta Matsukuma, Kanako Iwamura, Y Zhang et autres

jp (code pays fourni par la source)

Direct Flow Cytometric Assessment of Cerebrospinal Fluid CAR-T Cells for ICANS Diagnosis

Koji Kato, Ken Takigawa, Kohta Miyawaki, Shiho Taniguchi et autres

jp (code pays fourni par la source)

WCN26-7717 A CASE OF RENAL CYST INFECTION DEVELOPING FULMINANT DRUG-INDUCED IMMUNE THROMBOCYTOPENIC PURPURA DURING MULTIPLE ANTIBIOTIC THERAPY

Kanako Iwamura, Yuta Matsukuma, Narumichi Iwamura, Teppei Sakoda et autres

jp (code pays fourni par la source)

Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL

Kohei Yamaguchi, Takuji Yamauchi, Seiya Hirakawa, H. Nakagaki et autres

jp (code pays fourni par la source)

Guanine nucleotides drive ribosome biogenesis and glycolytic reprogramming in acute myeloid leukemia stem cells

Gentaro Kawano, Daisuke Ishihara, Takahiro Shima, Teppei Sakoda et autres

ABSTRACT: Therapy resistance in acute myeloid leukemia (AML) remains a major clinical obstacle, particularly because of the persistence of leukemia stem cells (LSC) capable of metabolic adaptation. Although venetoclax (Ven) inhibits oxidative phosphorylation (OXPHOS), we found that Ven-resistant LSC undergo glycolytic reprogramming …

jp (code pays fourni par la source)

Engraftment syndrome after PD-1 blockade in classical Hodgkin lymphoma treated by autologous stem cell transplantation

Takuji Yamauchi, Yasuo Mori, C. Matsuo, H. Nishihara et autres

Immune checkpoint inhibitors (CPIs) targeting PD-1, such as nivolumab and pembrolizumab, have become integral to the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL), frequently serving as a bridge to autologous stem cell transplantation (ASCT). However, recent reports suggest that CPI …

jp (code pays fourni par la source)

Burkitt in disguise: clonal transformation of incidentally detected gallbladder diffuse large B-cell lymphoma in a liver transplant recipient

Kohta Miyawaki, Yasuo Mori, Yuichiro Semba, H. Nishihara et autres

jp (code pays fourni par la source)

KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML

Haruka Kinosada, Shin‐ichiro Takayanagi, Toshihiko Ishii, Toru Amano et autres

Acute myeloid leukemia (AML) is a common hematopoietic malignancy with high recurrence rates, and there is an urgent need for new therapeutic agents. T-cell immunoglobulin mucin-3 (TIM-3) is expressed on the surface of both LSCs and blasts in most AML patients, but …

jp (code pays fourni par la source)

Objective quantification of pre-CAR-T EEG abnormalities for ICANS prognosis: insights from GTE scoring

Takuji Yamauchi, Takahiko Mukaino, Ayumi Sakata, Eriko Watanabe et autres

jp (code pays fourni par la source)

Cerebrospinal fluid proteomics exerts predictive potential for immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR-T cell therapy

Tomoko Nomiyama, Daiki Setoyama, Ikumi Yamanaka, Masatoshi Shimo et autres

Chimeric Antigen Receptor (CAR) T-cell therapy is a potent immunotherapy for B cell malignancies, employing genetically engineered T cells to target CD19 [ 1 ]. Despite high response rates, it is associated with toxicities like cytokine release syndrome (CRS) and immune effector …

jp (code pays fourni par la source)